A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL 5859 in Subjects With Rheumatoid Arthritis.

Trial Profile

A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL 5859 in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs ADL 5859 (Primary) ; Naproxen
  • Indications Musculoskeletal pain; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Adolor Corporation
  • Most Recent Events

    • 19 Dec 2008 Results presented in a Adolor media release.
    • 04 Dec 2008 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 04 Dec 2008 Company Cubist Pharmaceuticals added to the associations field as reported by ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top